Avadel pharma announces positive topline results from pivotal phase 3 rest-on trial

Avadel pharmaceuticals announces positive topline results from its pivotal phase 3 rest-on trial of once-nightly ft218 for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.avadel pharmaceuticals plc - once-nightly ft218 at 9 g was generally well-tolerated.avadel pharmaceuticals - once-nightly ft218 at 7.5 g and 6 g dose levels achieved highly statistically significant clinically meaningful improvements.avadel pharma- once-nightly ft218 at 9 g demonstrated highly statistically significant, clinically meaningful improvement across 3 co-primary endpoints.
AVDL Ratings Summary
AVDL Quant Ranking